Christian Schmithals

Goethe University Frankfurt — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index619citations49works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(25), Epigenetics and DNA Methylation(7), MicroRNA in disease regulation(6), Hepatocellular Carcinoma Treatment and Prognosis(6), Nanoplatforms for cancer theranostics(6)

Publications49 total

Discovery of 7,9-Dibromo-dihydrodibenzofuran as a Potent Casein Kinase 2 (CK2) Inhibitor: Synthesis, Biological Evaluation, and Structural Studies on <i>E-</i>/<i>Z</i>-Isomers
ACS Pharmacology & Translational Science·2024· 1 citedOpen Access
Das Tumorgefäß-Targeting iRGD-Peptid verbessert durch einen induzierten Tumor-Blut-Transport die diagnostische Genauigkeit von Tumormarkern
Zeitschrift für Gastroenterologie·2024
Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice
EBioMedicine·2024· 3 citedOpen Access
Tumour-specific activation of a tumour-blood transport that may improve the diagnostic accuracy of blood tumour markers
Zeitschrift für Gastroenterologie·2024
Supplementary Table S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Data from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Data from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Table S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Figure S2 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Supplementary Figure S1 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Data from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Albrecht Piiper(47), Thomas Pleli(38), Stefan Zeuzem(35), Oliver Waidmann(35), Bianca Kakoschky(33), Verena Köberle(32), Bernd Kronenberger(29), Horst‐Werner Korf(27), Ahmed Atef Ibrahim(25), Thomas J. Vogl(19), Fabian Finkelmeier(18), Andreas Weigert(17), Otto Kollmar(15), Rolf Marschalek(15), Hüdayi Korkusuz(14), Scarlett Nitsch(14), Tobias Schmid(14), Erik Kowarz(13), José M. Arencibia(12), Eduardo Alonso Augusto(11)